Jasper Therapeutics, Inc. (JSPR) stock
JSPRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.34−1.43 (-12.15%)
Close on Nov 17, 2026Market cap $344.06MP/E –Yield –
Jasper Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Jasper Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$55.16M. For fiscal 2025 it was -$83.88M. The highest annual figure on record is -$20.68M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$83.88M | – |
| FY2024 | Dec 31, 2024 | -$76.24M | – |
| FY2023 | Dec 31, 2023 | -$68.86M | – |
| FY2022 | Dec 31, 2022 | -$51.20M | – |
| FY2021 | Dec 31, 2021 | -$36.83M | – |
| FY2020 | Dec 31, 2020 | -$20.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.21M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.95M | – |
| Q4 FY2025 | Dec 31, 2025 | -$15.84M | – |
| Q3 FY2025 | Sep 30, 2025 | -$19.17M | – |
| Q2 FY2025 | Jun 30, 2025 | -$27.08M | – |
| Q1 FY2025 | Mar 31, 2025 | -$21.80M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.29M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.89M | – |
| Q2 FY2024 | Jun 30, 2024 | -$15.99M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.07M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.83M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.95M | – |
| Q4 FY2022 | Dec 31, 2022 | -$13.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.71M | – |
| Q2 FY2022 | Jun 30, 2022 | -$11.96M | – |
| Q1 FY2022 | Mar 31, 2022 | -$12.78M | – |
| Q4 FY2021 | Dec 31, 2021 | -$12.08M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.08M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.42M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.25M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.96M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.01M | – |
| Q2 FY2020 | Jun 30, 2020 | -$327.56K | – |
| Q1 FY2020 | Mar 31, 2020 | -$228.67K | – |
See a number that looks wrong?